At the ongoing SupplySide West trade show in Las Vegas, US (October 30–31), Rousselot has unveiled the results of the first clinical study confirming the health benefits of the company’s newly released Nextida GC product targeting post-meal glucose spikes. “The most surprising — and exciting — aspect of the entire Nextida platform for us is how it furthers our mission to decode the collagen molecule and its benefits, ” Catarina Ferreira da Silva, science integration manager at Rousselot, tells Nutrition Insight at the trade show.
